5 reports

  • AUG 29, 2017: ONCBIOMUNE TO PRESENT ABSTRACT ON CLINICAL TRIAL OF NOVEL PROSTATE CANCER VACCINE AT AMERICAN ASSOCIATION OF CANCER RESEARCH SPECIAL CONFERENCE
  • SEP 14, 2017: ONCBIOMUNE MEETS PRIMARY OBJECTIVE IN TRIAL OF PROSCAVAX IMMUNOTHERAPY VACCINE FOR PROSTATE CANCER

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H1 2018 Summary Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 15 molecules. Out of which...

  • Blood Supply
  • Cancer
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017
  • PIPELINE BY ONCBIOMUNE PHARMACEUTICALS INC, H2 2017

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H2 2017 Summary Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) pipeline Target constitutes...

  • Cancer
  • Monoclonal Antibody
  • Prostate Cancer
  • Therapy
  • OncBioMune Pharmaceuticals, Inc.
  • PROSTATE CANCER PATIENTS.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2018 Summary According to the recently published report ’Prostate Specific Antigen - Pipeline Review, H1 2018’; Prostate Specific Antigen (Gamma Seminoprotein...

  • Cancer
  • Prostate Cancer
  • United States
  • Product Initiative
  • OncBioMune Pharmaceuticals, Inc.
  • JUN 02, 2016: MEXICAN REGULATORY AUTHORITIES SUPPORTIVE OF ONCBIOMUNES PHASE 2 OF PROSCAVAX FOR PROSTATE CANCER
  • MAY 11, 2016: ONCBIOMUNE PROVIDES UPDATE ON PHASE 2 CLINICAL TRIALS OF PROSCAVAX FOR PROSTATE CANCER

Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) targeted pipeline therapeutics....

  • Cancer
  • Cytokine
  • Prostate Cancer
  • Vaccine
  • OncBioMune Pharmaceuticals, Inc.
  • VENTURE FINANCING
  • ONCBIOMUNE PHARMA AND VITEL LABS FORMS JOINT VENTURE

While known to be inherited and considered one of the most common genetic disorders worldwide, no one is certain as to how many people are afflicted with AAT deficiency.

  • Cancer
  • Mexico
  • United States
  • Company
  • OncBioMune Pharmaceuticals, Inc.